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ABSTRACT
Objective To synthesise indings from randomised 
controlled trials (RCTs) of interventions aimed at 
increasing medication adherence in individuals with type 
2 diabetes (T2DM) and/or cardiovascular disease (CVD). 
And, in a novel approach, to compare the intervention 
effect of studies which were categorised as being more 
pragmatic or more explanatory using the Pragmatic- 
Explanatory Continuum Indicator Summary-2 (PRECIS-2) 
tool, to identify whether study design affects outcomes. 
As explanatory trials are typically held under controlled 
conditions, indings from such trials may not be relatable 
to real- world clinical practice. In comparison, pragmatic 
trials are designed to replicate real- world conditions and 
therefore indings are more likely to represent those found 
if the intervention were to be implemented in routine care.
Design Systematic review and meta- analysis.
Data sources Ovid Medline, Ovid Embase, Web of Science 
and CINAHL from 1 January 2013 to 31 December 2018.
Eligibility criteria for selecting studies RCTs lasting ≥3 
months (90 days), involving ≥200 patients in the analysis, 
with either established CVD and/or T2DM and which 
measured medication adherence. From 4403 citations, 
103 proceeded to full text review. Studies published in 
any language other than English and conference abstracts 
were excluded.
Main outcome measure Change in medication 
adherence.
Results Of 4403 records identiied, 34 studies were 
considered eligible, of which 28, including 30 861 
participants, contained comparable outcome data for 
inclusion in the meta- analysis. Overall interventions were 
associated with an increase in medication adherence (OR 
1.57 (95% CI: 1.33 to 1.84), p<0.001; standardised mean 
difference 0.24 (95% CI: −0.10 to 0.59) p=0.101). The 
effectiveness of interventions did not differ signiicantly 
between studies considered pragmatic versus explanatory 
(p=0.598), but did differ by intervention type, with studies 
that included a multifaceted rather than a single- faceted 
intervention having a more signiicant effect (p=0.010). 
The analysis used random effect models and used the 
revised Cochrane Risk of Bias Tool to assess study quality.
Conclusions In this meta- analysis, interventions were 
associated with a signiicant increase in medication 
adherence. Overall multifaceted interventions which 
included an element of education alongside regular 
patient contact or follow- up showed the most promise. 
Effectiveness of interventions between pragmatic and 
explanatory trials was comparable, suggesting that 
indings can be transferred from idealised to real- word 
conditions.
PROSPERO registration number CRD42017059460.
INTRODUCTION
Prevalence of type 2 diabetes (T2DM) and 
cardiovascular diseases (CVDs) are increasing 
rapidly.1 They have been identified as two of 
the most common cardiometabolic morbidi-
ties associated with multimorbidity1 and are 
two of the leading causes of death worldwide.2 
Most people diagnosed with these conditions 
will likely have multimorbidity1 (coexistence 
Strengths and limitations of this study
 Ź In a novel approach, this systematic review com-
pared whether study design (pragmatic vs explan-
atory as deined by the Pragmatic- Explanatory 
Continuum Indicator Summary-2 (PRECIS-2) tool) 
had an impact on intervention effect.
 Ź The study selection was undertaken independently 
by two researchers to ensure that all relevant stud-
ies were included as well as preventing the risk of 
individual biases on study selection.
 Ź The impact of study heterogeneity was explored us-
ing subgroup analyses.
 Ź This review provides a contemporary update to the 
2014 Cochrane Review on medication adherence.
 Ź A potential limitation of this systematic review and 
meta- analysis is that a small number of studies had 
to be excluded as they did not categorise diabetes 
type.
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of two or more chronic conditions), particularly those 
aged 65–84 years where prevalence is estimated at 65%.3
Management of multimorbidity is complex, typically 
relying on the coprescription of multiple drugs, which is 
strongly associated with medication non- adherence.4 The 
WHO estimates that 50% of individuals receiving chronic 
treatment are non- adherent (taking less than 80%) to 
prescribed medications.5 Medication non- adherence 
is considered the biggest cause of suboptimal clinical 
outcomes, accounting for approximately 57% of avoid-
able costs in relation to medication use.5
Despite the rise in cardiometabolic multimorbidity,6–8 
interventions to increase medication adherence within 
this population are sparse. As such we decided to focus 
this review on T2DM and CVD as the most prevalent 
cluster cardiometabolic morbidities. Treatment non- 
adherence within these populations is well recognised 
and has become the focus of considerable research. While 
randomised controlled trials (RCTs) are widely accepted 
as a rigorous way of exploring the impact of interventions 
on specific health behavioural change outcomes, it has 
been identified that numerous components within a trial 
design can lead to biased interpretations of intervention 
effects.9 One such bias may be the controlled nature of 
these trials and the impact they impose on the cooper-
ation of their participants and may prelude an action 
which does not necessarily represent what may occur in 
routine clinical practice.10 In pragmatic trials, the inter-
vention is less strict and mimics usual practice as much 
as possible, thus lessening the unexpected reactions 
from the patients which lead to the biases.11 As RCTs 
are generally expensive to conduct, it is important that 
their findings show real- world intervention effectiveness 
that is relevant to routine clinical practice. This study 
therefore aimed to not only identify interventions to 
increase medication adherence but also compare the 
effectiveness of interventions categorised as explanatory 
(undertaken in idealised settings) or pragmatic (under-
taken in real- world settings). Described by Schwartz and 
Lellouch,12 explanatory trial are those which confirm 
a physiological or clinical hypothesis; in contrast, prag-
matic trails are those which inform clinical or policy deci-
sions by evidencing the effect that adoption would have 
on routine care. As treatment effects of explanatory trials 
may be larger than those observed in pragmatic trials, 
traditional meta- analytic approaches may not account for 
this heterogeneity resulting in biased estimated treatment 
effects. While a handful of reviews in different research 
areas have now been published which retrospectively 
applied PRECIS-2 (Pragmatic- Explanatory Continuum 
Indicator Summary-2) to see if comparing pragmatic 
with explanatory trials altered review findings,13 14 to 
the authors knowledge, this is the first review to incor-
porate PRECIS-2 scoring into the initial review process. 
While retrospective application provides an interesting 
comparison, whereby the overall intervention effects can 
be compared with explanatory and/or pragmatic inter-
vention effects, pre- or post- use of PRECIS-2, it could lead 
to an initial misinterpretation of findings. For example, 
a review containing a high number of explanatory trials 
may be much less applicable to routine clinical practice 
than one containing a greater number of pragmatic trials. 
Identification and comparison during the trial design 
stage would allow researchers to more easily identify 
how applicable findings would be to real- world clinical 
practice, rather than making an assumption based on a 
generalised outcome. In addition, this approach removes 
any risk of bias as the analysts are unaware of the results 
of the study. Using PRECIS-2 this review scored interven-
tions from very explanatory to very pragmatic to explore 
whether the differences in characteristics between the 
study designs of these trials influenced intervention effec-
tiveness estimates in a meta- analysis.
METHODS
This systematic review has been registered on PROS-
PERO and was conducted in accordance with PRISMA 
(Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses) guidelines.15
Data sources and searches
An extensive scoping search identified the great breath of 
research published within this topic area. It also identified 
a 2014 Cochrane Review on medication adherence which 
included studies published up to 11 January 2013. Due 
to factors relating to the focus of the review, changes in 
prescribed medication and the increasing use of mobile 
technology interventions in recent adherence research, 
we decided that this review would provide a contempo-
rary update and therefore we refined our literature search 
to include studies published between 1 January 2013 
to 31 December 2018. We searched Ovid Medline 1946 
(Epub ahead of print, in process and other non- indexed 
citations), Ovid Embase 1974, Web of Science 1970 and 
Cumulative Index of Nursing and Allied Health Litera-
ture (EBSCO CINAHL- plus with full text). We searched 
“type 2 diabetes”, “cardiovascular disease”, “medica-
tion adherence” and “randomised control trial” using a 
combination of medical subject headings, keywords and 
synonyms with both English and American spellings. An 
example search strategy can be found in online supple-
mentary etable 1.
Screening
Two investigators (CF and EI) independently screened 
all titles, abstracts and full text articles. Discrepancies 
were resolved through discussion with a third researcher 
(CG). Studies were assessed against five eligibility criteria 
to determine first, whether the study was an RCT; second, 
that patients were identified as having established CVD 
and/or T2DM; third, the trial measured medication 
adherence; fourth, study duration was ≥3 months (90 days) 
and fifth, the study included >200 people in the analysis. 
Studies published in any language other than English and 
conference abstracts were excluded. Additional reasons 
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for exclusion were where articles failed to specify diabetes 
type or where results were combined for individuals at 
risk of and with established CVD.
Data extraction
Data extraction was performed by CF and checked by CG. 
Where available the following data were recorded: study 
characteristics (authors, year, country, duration, sample 
size), participant characteristics (age, gender, disease), 
methods of assessment (self- report, pharmacy records, 
pill count), intervention type (online supplementary 
etable 2) and outcome measures of medication adher-
ence. For trials reporting multiple follow- up, the final 
follow- up corresponding to study duration was used.
Risk of bias
Risk of bias assessment was undertaken using the revised 
Cochrane Risk of Bias Tool for RCTs.16 17
Pragmatic-Explanatory Continuum Indicator Summary-2
Using Loudon et al (2015) for guidance,18 PRECIS-2 
scoring to explore how pragmatic/explanatory different 
components of the included study designs was under-
taken independently by CF and CG. Each of the nine 
domains was given a score from 1 (very explanatory ‘ideal 
study conditions’) to 5 (very pragmatic ‘usual care condi-
tions’). Results were compared and a consensus score was 
reached.
Some studies did not clearly explain all components 
making scoring difficult. To determine whether the 
treatment of unclear data affected the overall score, we 
conducted two classification processes. For the primary 
method we inputted a score of 3 and then calculated an 
average score by adding up the scores and dividing by 
9. In the second, a score was not given for the missing 
domains and then an average was calculated based on 
available domain scores.
Data synthesis
Study data were reported as means and medians for 
continuous data and as proportions for categorical data. 
Twenty- two studies defined a cut point to determine 
adherence. Twenty used a binary outcome defining 
individuals as adherent or non- adherent; however, two 
categorised individuals based on a prespecified level of 
low, medium and high. Of those reporting levels of low, 
medium or high adherence, as has been done in previous 
studies,19 20 we combined medium and high levels and 
separated low level to form a binary outcome of adher-
ence or non- adherence, respectively, therefore enabling 
OR of adherence to be calculated. In one study (Boyne 
et al, 2014), all participants in the intervention arm were 
adherent at follow- up, so a continuity correction of 0.5 was 
added to allow an OR to be calculated. Where an OR for 
medication adherence was reported in study results, this 
was used for the meta- analyses, rather than calculating 
an estimated OR from the raw numbers. Where adjusted 
ORs were reported, the OR adjusted for the most covari-
ates was used in the meta- analyses.
A further six studies, plus one which was included in 
the previous analysis, reported adherence using a contin-
uous scale which provided an overall group indication of 
adherence. For these studies, change in adherence for each 
study arm was calculated. As scores differed, we calculated 
standardised mean differences (SMDs) to combine study 
estimates in a meta- analysis. The SMD was calculated as the 
mean change in medication adherence in the intervention 
group minus mean change in the control group, divided by 
the pooled SD, using Cohen’s method.21
For both meta- analysis models, funnel plots and Egger’s 
test were carried out to assess for publication bias, and 
random effects meta- analyses were fitted to account for 
heterogeneity in study design. We assessed heterogeneity 
between studies by calculating the Higgins I² statistic, with 
an I² statistic >75% considered high heterogeneity.22 In one 
study (Boyne et al, 2014), all participants in the intervention 
arm were adherent at follow- up, so a continuity correction 
of 0.5 was added to allow an OR to be calculated.
We fitted meta- regression models assessing; study length, 
whether adherence was a primary or secondary outcome, 
mean age, percent male, disease (T2DM or CVD), and 
PRECIS-2 score, to explore the impact of study heterogeneity 
on the intervention effect. Three subgroup analyses were 
also carried out, whereby fitting a meta- regression model to 
compare the statistical difference between groups, separate 
meta- analyses were also run for each subgroup to enable 
the pooled estimate for each subgroup to be calculated, 
and hence a more explicit comparison to be made. The first 
compared intervention effects of studies that included a 
self- reported measure of adherence, to those with an objec-
tive adherence measure. The second compared pragmatic 
with explanatory studies (pragmatic studies were those with 
an average PRECIS-2 score >3 and explanatory a score of 
≤3) and the third compared outcomes of interventions 
which were identified as multifaceted against those with a 
singular intervention component.
Where studies had obtained both pharmacy and self- 
report data, pharmacy data were used in preference in the 
meta- analysis. In the case of a few studies which did not 
report overall level of adherence and instead listed indi-
vidual drug adherence, we made the pragmatic decision to 
monitor the adherence effect of the first drug listed by the 
author.
All analyses were performed using Stata 15 with the 
METAN, METAREG and METABIAS commands. Results 
are reported with 95% CIs with a p value <0.05 considered 
statistically significant. For the few studies not included 
within the meta- analysis, descriptive synthesis of interven-
tion effects is discussed.
RESULTS
Study selection
Following deduplication we screened 4403 titles and 
abstracts which yielded 103 potentially relevant studies. 
Thirty- three met the inclusion criteria with an additional 
study23 identified from reference list and forward citation 
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screening (figure 1).23 Of the 34 studies, 28 including 30 
861 participants contained comparable outcome data for 
inclusion in the meta- analysis.
Characteristics of included studies
An overview of the characteristics of the included studies 
is available in table 1. A more detailed key characteristics 
of included studies is available in online supplementary 
etable 3. Studies were conducted in 17 countries, with 
one study24 conducted across 4 countries. Twenty- three 
trials were conducted in high- income countries,23 25–46 
seven in upper middle,47–53 two in lower middle,54 55 
one in a low- income country and one across both upper 
middle and high income economies.56 The proportion of 
males ranged from 27.9%31 to 94.0%.23 Four trials did not 
report age24 26 52 56 and/or gender.24 26 56
Medical conditions varied across studies; 12 studies 
were in participants with T2DM,25 28–31 34 37 41 48 53 54 56 21 in 
participants with CVD23 24 26 27 32 33 35 36 38–40 42–44 46 47 49–52 55 
and 1 in people with both.45 Follow- up ranged from 3 to 
36 months.
Medication adherence was assessed as a primary outcome 
in 19 studies.24 25 27–29 33 35 36 39 42 44 45 48 50–53 55 56 Methods of 
measuring medication adherence varied between studies. 
Adherence was primarily assessed through self- report 
(n=23),23–32 34 38 40 42 44 47–50 53–56 followed by pharmacy 
data (n=10),28 35 36 41–43 45 46 50 53 pill count (n=2)24 33 and 
electronic pill bottle opening (n=1).39 Three studies did 
not report the method of medication adherence assess-
ment used.37 51 52 Of those measuring adherence through 
self- report, the Morisky- Green Questionnaire57 and the 
8- item Morisky Medication Adherence Scale (MMAS-8)58 
(or translated versions) were the most frequently used. 
Four studies measured adherence using two different 
methods: self- report and either pharmacy or pill count 
data.24 28 50 53 Two of the studies combined the data to 
provide an overall level or adherence,24 28 whereas the 
other two reported adherence outcomes separately.50 53 
Of the two studies reporting separate outcomes, both 
reported consistent findings and statistically significant 
improvements in adherence whether self- report or phar-
macy data were used.
Interventions varied greatly between studies. We cate-
gorised and defined interventions (online supplementary 
etable 2) based on their most prominent feature into one 
Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta- Analyses) low chart of included studies. CVD, 
cardiovascular disease; T2DM, type 2 diabetes mellitus.
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Table 1 Overview of characteristics of included studies
First author, year
Sample size (analysed)
Duration (data collection 
points) Condition Key intervention detail
Medication adherence 
measure
Al- Haj Mohd, 201625 446 (446)
6 months (0 and 6 months)
T2DM Multifaceted intervention strategy Self- report (MMAS-8)
Barker- Collo, 201526 386 (326)
12 months (0, 3, 6, 9 and 12 
months)
Stroke/TIA Behavioural/educational Self- report with crosscheck of 
pharmacy data
Boyne, 201427 382 (382)
12 months (0, 3, 6 and 12 
months)
Heart failure Telemonitoring/telemedicine Self- report (European Heart 
Failure Self- care Behaviour 
Scale)
Buhse, 201728 279 (279)
6 months (0 and 6 months)
T2DM Behavioural/educational Pharmacy data
Self- report (interview)
Caetano, 201829 709 (702)
6 months (0 and 6 months)
T2DM Behavioural/educational MAT scale
Cao, 201747 236 (236)
90 days (0, 30 and 90 days)
Coronary heart 
disease
Collaborative care Self- report (MMAS-8)
Carrasquillo, 201730 300 (215)
12 months (0 and 12 months)
T2DM Behavioural/educational Self- report (MMAS-8)
Castellano, 201424 695 (594)
9 months (0, 1, 4 and 9 
months)
Myocardial 
infarction
Simpliication of drug regimen Pill count
Self- report (Morisky- Green- 
Levine Adherence Scale)
Chung, 201448 241 (241)
12 months (0, 4, 8 and 12 
months)
T2DM Multifaceted intervention strategy Self- report—MMAS-8 (Revised 
Malaysian version)
Crowley, 201331 359 (329)
12 months (0, 3, 6, 9 and 12 
months)
T2DM Multifaceted intervention strategy Self- report (Morisky- Green- 
Levine Adherence Scale)
Du, 201632 979 (964)
36 months (0 and 36 months)
Percutaneous 
coronary 
intervention
Multifaceted intervention strategy Self- report (Morisky- Green- 
Levine Adherence Scale)
El- Touky, 201733 321 (276)
12 months (0, 1, 3, 6, 9 and 12 
months)
Acute coronary 
syndrome
Behavioural/educational 
intervention
Pill count
Graumlich, 201634 674 (674)
12 months (0, immediately 
postintervention, 3 and 6 
months)
T2DM Medication monitoring table Self- report (PMAQ)
Hedegaard, 201535 211 (203)
12 months (0, 3, 6, 9 and 12 
months)
Stroke/TIA Multifaceted intervention strategy Pharmacy data—MPR
Ho, 201436 253 (241)
12 months (0 and 12 months)
Acute coronary 
syndrome
Multifaceted intervention strategy Pharmacy reill data
Jeong, 201837 338 (338)
24 weeks (0 and 24 weeks)
T2DM Telemonitoring/telemedicine Does not report
Jia, 201749 669 (669)
36 months (0, 1, 3, 6, 12 and 
36 months)
Percutaneous 
coronary 
intervention
Intensiied patient care Self- report (Morisky- Green- 
Levine Adherence Scale)
Kronish, 201438 600 (600)
6 months (0 and 6 months)
Stroke/TIA Behavioural/educational 
intervention
Self- report (MMAS-8)
Lin, 201750 288 (288)
18 months (0, 6, 12 and 18 
months)
Coronary artery 
bypass grafting
Multifaceted intervention strategy Self- report—MARS (5 item)
Marin, 201556 467 (459)
12 months (0 and 12 months)
T2DM Personalised medication 
management
Self- report (Morisky- Green- 
Levine Adherence Scale)
Marquez- Contreras, 
201839
726 (625)
18 months (0, 6 and 12 
months)
Atrial ibrillation Multifaceted intervention strategy MEMs
Continued
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of the following seven groups: (1) behavioural/educa-
tional,23 26 28–30 33 34 38 40 41 44 51 53 54 (2) intensified patient 
care,42 49 (3) collaborative care,47 (4) simplification of 
drug regimen,24 (5) personalised drug dispensing,56 (6) 
telemonitoring/telemedicine27 37 45 and (7) multifaceted 
intervention strategy.25 31 32 35 36 39 43 46 48 50 52 55
PRECIS-2 scoring
Details of PRECIS-2 scoring for each of the included 
studies can be found in table 2. For the purpose of this 
study it was considered that each of the nine domains 
on the PRECIS-2 wheel had equal weighting. For visual 
clarity, PRECIS-2 results are presented as a shaded graph 
(table 2) where darker shades represent more pragmatic 
components. We also inputted scores on the PRECIS-2 
wheel (online supplementary efigures 1–3).
Of the 34 studies, 20 studies were identified as being 
more pragmatic, with an average score >3 (range 3.11–
4.11).23 24 26 27 29 32 35–37 40–49 52 Of these, most (n=18) 
received an average score between 3 and 4, demonstrating 
a slightly more pragmatic intention on the PRECIS-2 
continuum. Two of the studies scored ≥4,29 45 demon-
strating a greater degree of pragmatism. The majority 
of these studies scored poorly (score of 1) in relation 
to pragmatism of the primary outcome as, based on the 
guidance by Loudon et al,18 medication adherence was 
not considered of obvious importance from the patients’ 
perspective and was typically assessed by methods not 
First author, year
Sample size (analysed)
Duration (data collection 
points) Condition Key intervention detail
Medication adherence 
measure
Meng, 201423 471 (425)
12 months (admission, 
discharge, 6 and 12 months)
Coronary heart 
disease
Behavioural/educational 
intervention
Self- report—MARS- D
Meng, 201640 513 (449)
12 months (admission, 
discharge, 6 and 12 months)
Heart failure Behavioural/educational 
intervention
Self- report—MARS- D
Peng, 201451 3821 (3330)
12 months (discharge, 6, 9 and 
12 months)
Stroke/TIA Behavioural/educational 
intervention
Does not report
Pladevall, 201541 1692 (1512)
18 months (0, 6, 12 and 18 
months)
T2DM Behavioural/educational 
intervention
Pharmacy data—PDC
Rinfret, 201342 300 (300)
12 months (0 and 12 months)
Percutaneous 
coronary 
intervention
Intensiied patient care Pharmacy reill data
Samtia, 201354 348 (348)
5 months (0 and 5 months)
T2DM Behavioural/educational Self- report
Schou, 201443 921 (920)
13–72 months (every 1–3 
months)
Heart failure Multifaceted intervention strategy Pharmacy data—PDC
Schwalm, 201544 852 (852)
12 months (0, 3 and 12 
months)
Myocardial 
infarction
Behavioural/educational Self- report (Morisky- Green- 
Levine Adherence Scale)
Su, 201752 1275 (1187)
12 months (0 and 12 months)
Stroke/TIA Multifaceted intervention strategy Does not report
Vollmer, 201445 21 752 (21 752)
12 months (0 and 12 months)
T2DM and/or 
CVD
Telemonitoring/telemedicine Pharmacy data—PDC
Volpp, 201746 1509 (1503)
12 months (0 and 12 months)
Myocardial 
infarction
Multifaceted intervention strategy Pharmacy data—PDC
Xavier, 201655 805 (750)
12 months (0 and 12 months)
Acute coronary 
syndrome
Multifaceted intervention strategy Pharmacy data—composite 
medical adherence score 
>80%
Xin, 201553 240 (227)
12 months (0 and 12 months)
T2DM Behavioural/educational Prescription reill claims
Self- report (Morisky- Green- 
Levine Adherence Scale)
CVD, cardiovascular disease; MARS- D, Medication Adherence Report Scale (German version); MAT, Measure of Adherence to Treatments; MEMs, 
Medical Event Monitoring Systems; MMAS-8, Morisky Medication Adherence Scale (8- item); 0 months, baseline; MPR, medication possession ratio; 
PDC, proportion of days covered; PMAQ, Patient Medication Adherence Questionnaire; T2DM, type 2 diabetes mellitus; TIA, transient ischaemic 
attack.
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Table 2 Shaded graph to show PRECIS-2 scoring of included studies
First author Year Eligibility Recruitment Setting Organisation Flexibility: 
delivery
Flexibility: 
adherence
Follow- up Primary 
outcome
Primary 
analysis
Total 
score
Average 
score
Amended 
total score
Amended 
average score
Al- Haj Mohd25 2016 4 4 5 1 2 3 2 1 5 27 3 24 3
Barker- Collo26 2015 5 5 5 1 1 3 1 5 5 31 3.44 28 3.5
Boyne27 2014 5 5 5 2 1 3 1 2 5 29 3.22 26 3.25
Buhse28 2017 1 4 5 1 2 3 1 1 5 23 2.56 20 2.5
Caetano 29 2018 4 5 5 4 5 5 3 1 5 37 4.11 34 4.25
Cao47 2017 2 4 5 1 2 4 2 5 5 30 3.33 30 3.33
Carrasquillo 30 2017 1 1 4 1 2 1 1 2 4 17 1.89 17 1.89
Castellano 24 2014 4 5 5 5 5 2 2 1 5 34 3.78 34 3.78
Chung48 2014 2 5 5 4 1 5 2 1 5 30 3.33 30 3.33
Crowley 31 2013 1 1 5 2 2 3 2 2 4 22 2.44 19 2.38
Du 32 2016 5 4 5 2 2 3 2 5 5 33 3.67 30 3.75
El- Touky 33 2017 4 5 5 4 3 1 2 1 1 26 2.89 23 2.88
Graumlich 34 2016 1 2 5 1 1 4 2 2 5 23 2.56 23 2.56
Hedegaard 35 2015 4 4 5 2 2 3 4 1 5 30 3.33 27 3.38
Ho 36 2014 4 4 5 2 1 3 5 1 5 30 3.33 27 3.38
Jeong 37 2018 4 5 5 1 4 3 2 2 4 30 3.33 27 3.38
Jia 49 2017 3 4 5 2 4 3 4 1 4 30 3.33 27 3.38
Kronish 38 2014 4 1 4 1 2 3 1 2 5 23 2.56 20 2.5
Lin 50 2017 1 2 4 1 2 3 1 1 5 20 2.22 17 2.13
Marin 56 2015 1 2 5 4 4 3 2 1 4 26 2.89 23 2.88
Marquez- Contreras 39 2018 2 1 5 2 2 1 3 1 2 19 2.11 19 2.11
Meng 23 2014 4 5 5 2 4 3 2 2 4 31 3.44 28 3.5
Meng 40 2016 2 5 4 2 4 3 2 4 4 30 3.33 27 3.38
Peng 51 2014 3 5 5 2 1 3 3 1 4 27 3 21 3
Pladevall 41 2015 2 2 5 1 5 3 4 2 5 29 3.22 26 3.25
Rinfret 42 2013 4 4 5 2 4 3 4 1 5 32 3.56 29 3.63
Samtia 54 2013 2 4 4 4 3 3 1 2 4 27 3 21 3
Schou 43 2014 1 5 5 4 4 4 4 1 4 32 3.56 32 3.56
Schwalm 44 2015 5 5 5 4 4 3 2 1 4 33 3.67 30 3.75
Su 52 2017 4 5 5 2 2 3 2 1 4 28 3.11 25 3.13
Vollmer 45 2014 4 5 5 4 4 3 5 1 5 36 4 33 4.13
Volpp 46 2017 2 1 5 1 4 2 5 5 5 30 3.33 30 3.33
Xavier 55 2016 4 5 5 1 2 2 1 1 5 26 2.89 26 2.89
Xin 53 2015 2 3 3 2 4 3 2 1 4 24 2.67 15 2.5
PRECIS-2, Pragmatic- Explanatory Continuum Indicator Summary-2.
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used routinely in primary care. Eleven studies were iden-
tified as being more explanatory receiving an average 
score of <3 (range 1.89–2.89).28 30 31 33 34 38 39 50 53 55 56 Of 
these, most (n=10) received an average score between 2 
and 3 demonstrating that they favour a more explanatory 
intention on the continuum. Finally, three studies were 
given a score of 325 51 54 suggesting that these were equally 
pragmatic and explanatory.
The domains within which trials scored a more prag-
matic rating were recruitment, setting of the intervention 
and the primary analysis which received average scores of 
3.7, 4.8 and 4.4, respectively. All other domains appeared 
more explanatory with average scores of 2.2, 2.8, 2.9, 2.4 
and 1.8 for the domains of organisation, flexible delivery, 
flexible adherence, follow- up and primary outcome, 
respectively. The eligibility domain was the only one to 
receive a score of 3.
When results were compared based on the way missing 
data were scored, no changes to any studies overall cate-
gorisation was observed.
META-ANALYSIS
Effect of interventions
Data from 22 studies were pooled in a meta- analysis 
(figure 2). Irrespective of intervention type or duration, 
interventions significantly improved medication adher-
ence when compared with control (OR 1.57 (95% CI: 1.33 
to 1.84), p<0.001). For the seven studies where adherence 
was reported as a continuous variable, the pooled SMD 
was estimated as 0.24 ((95% CI: −0.10 to 0.59), p=0.101) 
(online supplementary efigure 4), in favour of the inter-
vention group, but was not statistically significant.
Both meta- analyses showed statistically significant 
heterogeneity between studies (p<0.001) with high I² 
values of 80.5% and 95.4% for the meta- analyses of the 
ORs and SMDs, respectively, where the I² value represents 
the percentage of variability due to heterogeneity rather 
than sampling error.
We investigated the heterogeneity by conducting meta- 
regression analyses (online supplementary etable 4). No 
statistically significant association was found between 
the intervention effects and study length, mean study 
age, male per cent, disease (CVD or T2DM), whether 
it was a primary or secondary outcome or PRECIS-2 
score. Subgroup analyses identified no differences in the 
intervention effect between self- reported and objective 
measures of adherence, and between PRECIS-2 score 
(online supplementary etable 5). Subgroup analyses 
comparing multifaceted versus singular- faceted inter-
ventions showed that multifaceted interventions led to 
Figure 2 Forest plot of pooled ORs for medication adherence, stratiied by Pragmatic- ExplanatoryContinuum Indicator 
Summary-2 (PRECIS-2) score.
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a statistically significant improvement in odds of adher-
ence (p=0.010) (figure 3; online supplementary figure 
S3, etable 5). The funnel plot and Egger’s test (p=0.184) 
showed that no indication of publication bias was present 
for the meta- analysis of SMDs (online supplementary 
efigure 5). For the meta- analysis of ORs, Egger’s test for 
publication bias was statistically significant (p=0.041), 
with the funnel plot asymmetry indicating a slightly 
uneven presence of small studies showing a favourable 
intervention effect (online supplementary efigure 6).
Descriptive synthesis
Six studies did not contain comparable data for inclusion 
in the meta- analysis.37 39 42 43 46 56 Of those, four studies 
showed a positive intervention effect on rates of medica-
tion adherence,37 39 42 56 while two showed no statistically 
significant intervention effects.43 46
Assessment of risk of bias
Table 3 displays trial specific risk of bias assessment. 
Few studies were deemed to be of fair quality with low 
risk of bias and none were considered to be free of bias. 
Twenty- seven trials provided information about adequate 
sequence generation and 17 regarding allocation 
concealment. Incomplete outcome data was a concern in 
four trials and selective reporting was primarily deemed 
unclear (n=19) due to the number of trials without 
a published protocol. Blinding of participants and 
personnel was the main domain scoring poorly for risk of 
bias; however, the nature of these types of trials means it 
is often impractical to do so.
DISCUSSION
Medication adherence is a key component of chronic 
disease care yet many patients fail to follow prescribing 
guidelines.5 This review identified 34 trials that evaluated 
the impact of interventions aimed at improving medica-
tion adherence in individuals with either T2DM and/
or established CVD. Overall interventions significantly 
increased medication adherence.
To our knowledge this is the first review to systemat-
ically compare and synthesise medication adherence 
outcomes based on the PRECIS-2 classification of trials. 
Our review showed that interventions improve medica-
tion adherence and the PRECIS-2 classification did not 
appear to affect the outcome when compared in subgroup 
and meta- regression analyses. This finding differs from 
previous research where explanatory trials have reported 
significantly larger effect sizes than pragmatic trials.13 14 
This suggests that findings from these interventions are 
representation of real- world clinical practice.
Figure 3 Forest plot of ORs for adherence, stratiied by complexity of the intervention.
10 Fitzpatrick C, et al. BMJ Open 2020;10:e036575. doi:10.1136/bmjopen-2019-036575
Open access 
Using the PRECIS-2 tool retrospectively posed a number 
of challenges. Missing data in published manuscripts is 
a known problem when conducting systematic reviews, 
and posed additional problems for this review as manu-
scripts often did not include the level of detail required to 
accurately score certain domains (online supplementary 
etable 6). As has been identified in previous research,59 
the most challenging domains to score were those 
relating to the flexibility of delivery and flexibility of 
participant adherence. Most studies focused on detail the 
content of the intervention not its delivery and adher-
ence. To define a study as having a more pragmatic or 
Table 3 Revised Cochrane risk of bias of included studies
First author, year
Adequate 
random 
sequence 
generation
Allocation 
concealment
Blinding of 
participants
Blinding of 
personnel
Blinding of 
outcome 
assessors
Incomplete 
outcome 
data
Selective 
reporting Other
Al- Haj Mohd25 + + – – ? + ? ?
Barker- Collo et 
al 26
+ + – – + – + +
Boyne 27 + ? ? ? ? + ? ?
Buhse 28 + + – – + + – +
Caetano29 + ? – – – + ? ?
Cao47 + + – – + + ? ?
Carrasquillo30 + + – – + + + ?
Castellano 24 + + – – – + + +
Chung 48 ? ? – – – + ? ?
Crowley 31 + + – – – + + ?
Du32 + + – – ? + ? ?
El- Touky 33 ? ? ? ? ? – ? ?
Graumlich 34 + + – – – + + +
Hedegaard 35 + + – – + + ? ?
Ho 36 + + ? ? + + + +
Jeong 37 ? ? – – – + – ?
Jia 49 ? + ? ? ? – ? ?
Kronish 38 + + – – + + ? ?
Lin 50 + ? ? ? + + ? ?
Marin 56 + ? ? ? ? + – –
Marquez- Contreras 
39
+ + ? ? ? – ? ?
Meng 23 – – – – – + ? ?
Meng 40 + + + + ? + + ?
Peng 51 + ? ? ? ? ? + ?
Pladevall41 + ? – – + + ? –
Rinfret 42 + + – – + + ? ?
Samtia 54 ? ? ? ? ? + ? –
Schou 43 + + – – – + + –
Schwalm44 + – ? ? + + + –
Su et al 52 + ? ? ? ? – ? ?
Vollmer 45 + ? – – – + ? ?
Volpp 46 + ? – – + + – ?
Xavier 55 + ? – – – + + ?
Xin 53 ? ? – – + + ? ?
Key: + low risk of bias, –high risk of bias, ? unclear risk of bias.
11Fitzpatrick C, et al. BMJ Open 2020;10:e036575. doi:10.1136/bmjopen-2019-036575
Open access
explanatory tendencies, we averaged domain scores to 
>3 or ≤3, respectively. While considered the best method, 
we were aware of problems which could arise as a result 
of combining data in this way. Combining scores could 
result in two or more studies receiving the same or similar 
scores even though individual domain scores were very 
different. It also meant that each domain was given equal 
weighting in the overall score of pragmatism. While a 
known limitation to the authors, no published guidance 
on how best to report the data could be found.
We restricted our review to articles published since 
2013 to provide a contemporary update following a large 
Cochrane review published 2014 by Nieuwlaat et al.60 
Similarly to the 2014 review, our findings suggest that 
interventions were diverse in nature and the majority 
were complex, involving multiple different components. 
Of the number of ‘successful’ interventions, multifac-
eted interventions which included an element of educa-
tion alongside regular patient contact showed the most 
promise, suggesting that frequent engagement with the 
healthcare team may trigger behavioural change or act as 
a reminder to undertake the behaviour. While promising, 
considerations need to be made as to the ability of such 
interventions to be upscaled and implemented. Multifac-
eted interventions can be expensive and therefore their 
cost utility needs to be explored prior to such interven-
tions becoming embedded in clinical care pathways.
As the number of people with access to mobile technol-
ogies has increased in the past decade, particularly in the 
over 60 age group, interventions which rely on frequent 
patient contact are becoming increasingly plausible and 
contact via either calls or SMS provide both a pragmatic 
and cheap alternative to face- to- face healthcare profes-
sional contact.61 A systematic review by Changizi and 
Kaveh looking into the effectiveness of mobile health in 
the elderly showed that it can be used effectively and is 
widely accepted as a source of health literacy, particularly 
SMS messages due to their low requirement for techno-
logical competency.62
Our review highlighted a number of limitations to 
medication adherence research conducted to date. First, 
the lack of gold standard method of measuring adher-
ence makes it difficult to pool and compare outcomes. 
The most frequently used method within this review was 
self- report, particularly the tools developed by Morisky 
and colleagues.57 58 These tools are quick, easy and cost- 
effective to administer making them ideal for use within 
a clinical care setting. The tools are validated and have 
shown moderate comparability with other indirect 
methods of medication adherence; however, their use 
has been associated with overestimation of true treatment 
adherence as they carry the potential for recall bias.63
Even among the studies using the Morisky scales 
methods of scoring and presenting data varied. For 
example, in the case of the Morisky- Green Scale, some 
used a Likert scoring system,31 some classed answers of 
no to all questions as indicative of good adherence,44 
whereas others classed good adherence as an answer of 
yes to all.53 For the MMAS-8, studies such as Cao et al47 
reported mean patient scores, with higher scores repre-
senting greater adherence. In contrast, Al- Haj Mohd et 
al
25 report the proportion of people categorised as low 
medium or highly adherent based on a score of <6, 6–7.9 
or >8, respectively. Discrepancies in reporting make it 
difficult to compare outcomes and therefore there is a 
need for standardisation. The best method to measure 
medication adherence across disease populations, and 
the best approach to reporting said results, therefore 
continues to be an area requiring further exploration.
We also acknowledge that our findings may be limited 
by our strict inclusion criteria. All papers reviewed were 
written in English and published since 2013 and therefore 
results may not represent non- English and older research. 
Finally the lack of quality of included studies, particularly 
in relation to participant blinding and reporting bias 
could compromise the integrity of review findings. In 
addition, there was some indication of publication bias 
for the meta- analysis of ORs (p=0.041). This suggest that 
some smaller studies showing a negative result might not 
have been published; therefore, the results of this meta- 
analysis need to be interpreted with some caution.
CONCLUSION
This systematic review showed that interventions had a 
significant effect on improving medication adherence in 
populations with T2DM and/or CVD. Multifaceted inter-
ventions which included either regular patient contact or 
an element of education had the most significant effect. 
There is, however, a need to compare more standardised 
interventions and assess these using more uniform 
methods of measuring medication adherence to enable 
studies to be more realistically compared.
With regard to trial design, recently there has been a 
focus on designing trials that are pragmatic and there-
fore more representative of ‘real life’. The findings from 
this review suggest that the effectiveness of interventions 
between pragmatic and explanatory trials was compa-
rable, suggesting that findings can be transferred from 
idealised to real- word conditions. There is, however, 
a need for further guidance to be developed to assist 
researchers in characterising and scoring studies.
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